Charles River Laboratories International (NYSE:CRL) Earns Neutral Rating from UBS Group

Charles River Laboratories International (NYSE:CRL)‘s stock had its “neutral” rating reissued by research analysts at UBS Group in a research report issued on Friday,Benzinga reports. They currently have a $185.00 price target on the medical research company’s stock, down from their previous price target of $250.00. UBS Group’s price objective points to a potential upside of 11.72% from the company’s previous close.

CRL has been the subject of several other research reports. Evercore ISI upped their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. Bank of America cut their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a research note on Monday, November 18th. TD Cowen boosted their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research report on Monday, November 11th. Finally, Robert W. Baird reduced their target price on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating on the stock in a report on Friday, September 20th. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $209.00.

Charles River Laboratories International Stock Down 4.8 %

Shares of CRL opened at $165.60 on Friday. Charles River Laboratories International has a 12 month low of $160.85 and a 12 month high of $275.00. The firm’s 50 day moving average is $191.67 and its 200-day moving average is $198.72. The stock has a market capitalization of $8.47 billion, a PE ratio of 20.73, a P/E/G ratio of 6.62 and a beta of 1.38. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company’s revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the company earned $2.72 EPS. Equities research analysts forecast that Charles River Laboratories International will post 10.18 EPS for the current year.

Insider Activity

In other news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares of the company’s stock, valued at $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 1.30% of the company’s stock.

Institutional Investors Weigh In On Charles River Laboratories International

Several hedge funds have recently added to or reduced their stakes in the business. Mitchell & Pahl Private Wealth LLC lifted its holdings in shares of Charles River Laboratories International by 8.8% during the fourth quarter. Mitchell & Pahl Private Wealth LLC now owns 3,603 shares of the medical research company’s stock worth $665,000 after purchasing an additional 292 shares during the period. Kera Capital Partners Inc. acquired a new stake in Charles River Laboratories International in the fourth quarter valued at $246,000. Pinnacle Bancorp Inc. raised its position in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares during the last quarter. Fiduciary Financial Group LLC lifted its holdings in Charles River Laboratories International by 3.9% during the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock worth $310,000 after buying an additional 63 shares during the period. Finally, Czech National Bank lifted its holdings in Charles River Laboratories International by 5.4% during the 4th quarter. Czech National Bank now owns 11,088 shares of the medical research company’s stock worth $2,047,000 after buying an additional 571 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).